Affinage

Showing ADGRD1GPR133 is a alias.

ADGRD1

Adhesion G-protein coupled receptor D1 · UniProt Q6QNK2

Length
874 aa
Mass
96.5 kDa
Annotated
2026-06-09
24 papers in source corpus 15 papers cited in narrative 15 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ADGRD1 (GPR133) is an adhesion G protein-coupled receptor that transduces extracellular and mechanical cues into intracellular cAMP signaling to control reproductive, skeletal, metabolic, and tumor-cell biology (PMID:22025619, PMID:33623007, PMID:40583059). It couples to Gs to activate adenylyl cyclase and elevate cAMP, and also engages G13 (PMID:22025619, PMID:40570642). Activation is governed by a tethered-agonist mechanism: the receptor undergoes autoproteolytic cleavage at its GAIN/GPS site shortly after synthesis, generating an N-terminal fragment (NTF) that stays noncovalently associated with the C-terminal fragment until it dissociates at the plasma membrane, exposing the intramolecular Stachel sequence that inserts into the transmembrane domain to drive signaling (PMID:25533341, PMID:34022221, PMID:35418679). Cryo-EM structures have resolved how the stalk engages the transmembrane domain through a conserved cascade of inter-helix interaction cores, including a cleavage-independent mode of activation (PMID:35418679, PMID:40570642). Receptor output is tuned by binding partners: the extracellular protein PTK7 binds the NTF and allosterically potentiates signaling in a cleavage-dependent, membrane-anchored manner topographically distinct from Stachel activation (PMID:37354459), mechanical force enhances activity (PMID:40583059), and the Ca2+-dependent ER-plasma membrane tether ESYT1 binds intracellularly to suppress signaling, an inhibition relieved by cytosolic Ca2+ elevation (PMID:38758649). Plxdc2 displayed on cumulus cells acts as an activating ligand controlling oviductal fluid flow and embryo transit, loss of which renders female mice sterile (PMID:33623007). Through cAMP signaling, ADGRD1 promotes osteoblast differentiation and bone formation via the β-catenin pathway and inhibits osteoclastogenesis via cAMP-PKA-NFATC1, with its loss producing osteoporosis-like skeletal defects (PMID:40583059, PMID:40644539); it also promotes adipogenesis and metabolic homeostasis (PMID:39821834) and supports glioblastoma stem-cell growth, where it is upregulated by HIF-1α-dependent hypoxic transcription (PMID:27775701).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 2011 High

    Established the core transduction logic of the receptor by showing GPR133 couples to Gs and elevates cAMP independently of its ectodomain or proteolytic cleavage.

    Evidence Gαs knockdown/overexpression, chimeric G protein routing, missense mutagenesis and cAMP assay

    PMID:22025619

    Open questions at the time
    • Did not identify the physiological activating input
    • Mechanism of receptor activation at the molecular level unresolved
  2. 2014 High

    Defined the activation mechanism by identifying the Stachel sequence as an intramolecular tethered agonist that engages the seven-transmembrane domain.

    Evidence Peptide agonist assay plus zebrafish Stachel-mutant genetic rescue across two aGPCRs

    PMID:25533341

    Open questions at the time
    • How ectodomain conformational change exposes the Stachel in vivo not resolved
    • Endogenous triggers of exposure unknown
  3. 2016 High

    Linked GPR133 to a disease context by showing it sustains glioblastoma stem-cell growth through cAMP and is transcriptionally induced by hypoxia.

    Evidence shRNA knockdown, tumorsphere and xenograft assays, forskolin rescue, HIF-1α-dependent transcription analysis

    PMID:27775701

    Open questions at the time
    • Endogenous activating ligand in GBM not identified
    • Downstream effectors beyond cAMP not mapped
  4. 2016 Medium

    Connected receptor function to natural sequence variation by functionally classifying loss- and gain-of-function ADGRD1 missense variants.

    Evidence Site-directed mutagenesis and cAMP functional assay

    PMID:27516204

    Open questions at the time
    • Single-lab functional characterization without in vivo validation
    • Physiological consequences of variants unknown
  5. 2021 High

    Resolved how cleavage controls activation by showing NTF-CTF dissociation at the plasma membrane promotes signaling, with cleavage-competent receptor producing more cAMP than the uncleavable mutant.

    Evidence Subcellular fractionation, Co-IP, H543R uncleavable mutant, PAR1-CTF chimeric proxy with thrombin, cAMP assay

    PMID:34022221

    Open questions at the time
    • Physiological driver of NTF dissociation in native tissue unknown
    • Whether dissociation is required or sufficient for full activation not fully resolved
  6. 2021 High

    Defined a physiological role and an activating ligand by showing Adgrd1 controls oviductal fluid flow and embryo transit, with Plxdc2 on cumulus cells acting as ligand.

    Evidence Constitutive KO mice, oviductal fluid-flow measurement, AVEXIS interaction screen, embryo transit imaging

    PMID:33623007

    Open questions at the time
    • Signaling pathway downstream of Plxdc2-Adgrd1 in oviduct not dissected
    • Whether Plxdc2 acts via the Stachel mechanism unknown
  7. 2022 High

    Provided the structural basis of tethered-agonist activation by resolving cryo-EM structures showing the stalk engages the transmembrane domain through a conserved inter-helix cascade, including cleavage-independent activation.

    Evidence Cryo-EM of ADGRD1/ADGRF1-Gs complexes, mutagenesis, functional signaling assays

    PMID:35418679

    Open questions at the time
    • Structures captured Gs-bound state only
    • Conformational transition from inactive to active state not visualized
  8. 2022 Medium

    Demonstrated that NTF-directed antibodies can pharmacologically activate the receptor in a cleavage-dependent manner, validating NTF dissociation as a druggable activation step.

    Evidence Antibody treatment of HEK293T and GBM cells, cAMP assay, H543R control, NTF immunoprecipitation

    PMID:35447113

    Open questions at the time
    • Single-lab study without independent replication
    • Therapeutic applicability in vivo not tested
  9. 2023 High

    Identified PTK7 as an extracellular allosteric positive modulator that binds the NTF and potentiates signaling distinctly from orthosteric Stachel activation.

    Evidence Affinity proteomics, reciprocal Co-IP, cAMP assay, cleavage-deficient mutant, PTK7 membrane-anchoring test, GBM knockdown

    PMID:37354459

    Open questions at the time
    • Structural basis of PTK7-NTF interaction unresolved
    • Whether PTK7 modulation operates in non-GBM tissues not addressed here
  10. 2024 High

    Revealed intracellular negative regulation by showing ESYT1 binds GPR133 in a Ca2+-dependent manner to suppress signaling, an inhibition relieved by cytosolic Ca2+ elevation.

    Evidence BioID proximity proteomics, reciprocal Co-IP, ESYT1 KD/KO/overexpression, C2C domain mutagenesis, thapsigargin, cAMP and GBM growth assays

    PMID:38758649

    Open questions at the time
    • How ESYT1 binding mechanically suppresses receptor signaling unclear
    • Physiological Ca2+ stimuli that gate this regulation in vivo unknown
  11. 2024 Medium

    Extended receptor function to innate immunity by showing GPR133 upregulation impairs macrophage phagocytosis.

    Evidence 5-Aza-dC demethylation, siRNA/shRNA knockdown, phagocytosis assays in decidual and THP-1 macrophages

    PMID:38564758

    Open questions at the time
    • Single-lab functional study
    • Signaling pathway linking GPR133 to phagocytic suppression not defined
  12. 2025 High

    Established a skeletal role by showing GPR133 promotes osteoblast differentiation and bone formation via mechanical force, PTK7, and cAMP/β-catenin signaling, with a tractable agonist alleviating osteoporosis.

    Evidence Constitutive and osteoblast-specific KO mice, stretch and mechanical loading assays, β-catenin pathway analysis, AP503 agonist in ovariectomy model

    PMID:40583059

    Open questions at the time
    • Molecular link between mechanical force and Stachel/NTF dynamics not resolved
    • How cAMP feeds into β-catenin mechanistically not fully defined
  13. 2025 High

    Showed ADGRD1 negatively regulates osteoclastogenesis via cAMP-PKA-NFATC1 and identified a Stachel-mimicking small-molecule agonist that prevents bone loss.

    Evidence GL64 small-molecule agonist, cAMP/PKA/NFATC1 pathway analysis, osteoclast differentiation assay, ovariectomy model

    PMID:40644539

    Open questions at the time
    • Cell-type specificity of GL64 action not fully delineated
    • Whether osteoblast and osteoclast effects are cell-autonomous not resolved
  14. 2025 Medium

    Expanded signaling repertoire by demonstrating G13 coupling and constitutive Stachel-driven self-activation, with a cryo-EM GAIN-miniGα13 structure.

    Evidence Cryo-EM at 3.51 Å, in vitro reconstitution of GPR133-GAIN-miniGα13, G13 signaling assay

    PMID:40570642

    Open questions at the time
    • Single-lab structure without independent replication
    • Physiological contexts requiring G13 versus Gs signaling unknown
  15. 2025 Medium

    Demonstrated a metabolic role by showing ADGRD1 promotes adipocyte progenitor differentiation and improves metabolic homeostasis, with MEF2D and TCF12 controlling its expression.

    Evidence Single-nucleus trajectory inference, primary APC differentiation, gain/loss-of-function in HFD mice, ChIP-seq and RNA-seq

    PMID:39821834

    Open questions at the time
    • Downstream signaling in adipocytes not connected to known cAMP mechanism
    • Activating ligand in adipose tissue not identified

Open questions

Synthesis pass · forward-looking unresolved questions
  • The endogenous activating inputs (ligands versus mechanical force) and the conformational sequence that exposes the Stachel in native tissues remain incompletely defined across the receptor's diverse physiological roles.
  • No unified model of how tissue-specific ligands, force, and partner proteins converge on Stachel exposure
  • Inactive-state structure not resolved
  • Tissue-specific Gs versus G13 bias not mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 4 GO:0140096 catalytic activity, acting on a protein 1
Localization
GO:0005886 plasma membrane 3
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-1266738 Developmental Biology 3 R-HSA-1643685 Disease 1

Evidence

Reading pass · 15 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2011 GPR133 (ADGRD1) couples to Gs protein and activates the Gs/adenylyl cyclase pathway to elevate cAMP. Neither the N-terminal ectodomain nor cleavage at the GPCR proteolysis site is required for G protein signaling. Gs coupling was verified by Gαs siRNA knockdown, Gαs overexpression, chimeric Gq(s4) co-expression routing activity to PLC/IP pathway, and a transmembrane-domain missense mutation that abolished receptor activity without altering cell surface expression. siRNA knockdown of Gαs, overexpression of Gαs, chimeric G protein co-expression, missense mutagenesis, cAMP assay The Journal of biological chemistry High 22025619
2014 A short peptide sequence within the ectodomain of GPR133 (termed the Stachel sequence) functions as a tethered agonist; upon structural changes in the ectodomain, this intramolecular agonist is exposed to the seven-transmembrane domain to trigger G protein activation. The Stachel sequence shows high receptor specificity. Peptide agonist assay, zebrafish Stachel-mutant genetic rescue, exogenous peptide application in hypomorphic gpr126 mutants Cell reports High 25533341
2016 GPR133 knockdown reduces CD133+ glioblastoma stem cell prevalence, tumor cell proliferation, and tumorsphere formation in vitro, and markedly reduces tumor xenograft growth in vivo; the GPR133 knockdown phenotype is rescued by forskolin, indicating signaling is mediated through cAMP. GPR133 mRNA is transcriptionally upregulated by hypoxia in a HIF-1α-dependent manner. shRNA knockdown, tumorsphere assay, mouse xenograft implantation, forskolin rescue, HIF-1α-dependent transcription analysis Oncogenesis High 27775701
2016 Functional characterization of naturally occurring ADGRD1 missense variants identified several loss-of-function nsSNPs (A448D, Q600stop, C632fs, A761E, N795K) and one gain-of-function nsSNP (F383S) that significantly increased basal receptor activity. Site-directed mutagenesis, cAMP functional assay BMC genomics Medium 27516204
2021 GPR133 undergoes autoproteolytic cleavage shortly after protein synthesis; the N-terminal fragment (NTF) and C-terminal fragment (CTF) remain noncovalently associated until the receptor is trafficked to the plasma membrane, where NTF-CTF dissociation occurs. Cleavage-competent WT GPR133 generates significantly more cAMP than the uncleavable H543R mutant. A PAR1-CTF/GPR133-NTF proxy system confirmed that thrombin-induced NTF shedding increases intracellular cAMP, supporting a model where NTF dissociation at the plasma membrane promotes receptor activation. Subcellular fractionation, co-immunoprecipitation, uncleavable point mutant (H543R), PAR1 chimeric proxy system with thrombin cleavage, cAMP assay The Journal of biological chemistry High 34022221
2021 Adgrd1 is expressed on oviductal epithelium; female mice lacking Adgrd1 are sterile due to failure to relieve the ampullary-isthmic junction (AIJ) restraining mechanism, causing inappropriate retention of embryos in the oviduct. Post-ovulatory attenuation of tubal fluid flow is dysregulated in Adgrd1-deficient mice. The extracellular protein Plxdc2, displayed on cumulus cells, was identified as an activating ligand for Adgrd1 by a large-scale extracellular protein interaction screen. Constitutive knockout mice, oviductal fluid flow measurement, large-scale extracellular protein interaction screen (AVEXIS), embryo transit imaging Nature communications High 33623007
2022 Cryo-EM structures of ADGRD1 (and ADGRF1) in complex with Gs protein revealed that the stalk region preceding the first transmembrane helix acts as the tethered agonist by forming extensive interactions with the transmembrane domain; an autoproteolysis-deficient ADGRF1 structure showed a cleavage-independent manner of receptor activation. A conserved cascade of inter-helix interaction cores mediates stalk-induced activation. Cryo-EM structure determination, mutagenesis, functional signaling assays Nature High 35418679
2022 Antibodies targeting the N-terminus of GPR133 increase cAMP in a concentration-dependent manner. This effect requires autoproteolytic cleavage: cells expressing the cleavage-deficient H543R mutant did not respond to antibody stimulation. Antibody treatment promotes release of the autoproteolytically cleaved NTF, supporting the model that NTF dissociation promotes receptor activation. Antibody treatment of HEK293T cells and patient-derived GBM cells, cAMP assay, cleavage-deficient mutant (H543R), immunoprecipitation of NTF from conditioned medium The Journal of biological chemistry Medium 35447113
2023 PTK7 is an extracellular binding partner of GPR133 in glioblastoma, identified by affinity proteomics. PTK7 binds the autoproteolytically generated NTF of GPR133 and its expression in trans increases GPR133 signaling. This allosteric effect requires GPR133 intramolecular cleavage and PTK7 anchoring in the plasma membrane. PTK7's allosteric action is additive with but topographically distinct from orthosteric Stachel peptide activation. Affinity proteomics, co-immunoprecipitation, cAMP assay, cleavage-deficient mutant, PTK7 transmembrane-anchoring requirement test, shRNA knockdown in GBM Cell reports High 37354459
2024 ESYT1, a Ca2+-dependent mediator of ER-plasma membrane bridge formation, is an intracellular interactor of GPR133 identified by proximity biotinylation proteomics. ESYT1 knockdown/knockout increases GPR133 signaling; overexpression suppresses it without altering plasma membrane GPR133 levels. The interaction requires the Ca2+-sensing C2C domain of ESYT1. Thapsigargin-mediated cytosolic Ca2+ elevation promotes ESYT1-GPR133 dissociation, relieving the signaling-suppressive effect. Proximity biotinylation proteomics (BioID), co-immunoprecipitation, ESYT1 KD/KO and overexpression, domain mutagenesis (C2C), thapsigargin treatment, cAMP assay, GBM tumor growth assay Cell reports High 38758649
2025 Constitutive and osteoblast-specific knockouts of Gpr133/Adgrd1 in mice cause reduced cortical bone mass and trabecularization characteristic of osteoporosis, due to impaired osteoblast function and increased osteoclast activity. GPR133/ADGRD1 regulates osteoblast differentiation through a combined mechanism involving PTK7 interaction and mechanical forces (demonstrated by stretch assays in vitro and mechanical loading in vivo). Downstream signaling proceeds via cAMP-dependent activation of the β-catenin pathway. Pharmacological activation with agonist AP-970/43482503 (AP503) enhances osteoblast function and alleviates osteoporosis in ovariectomized mice. Constitutive and osteoblast-specific knockout mice, in vitro stretch assay, in vivo mechanical loading, cAMP assay, β-catenin pathway analysis, pharmacological agonist treatment, ovariectomy osteoporosis model Signal transduction and targeted therapy High 40583059
2025 The small molecule GL64, identified as a selective ADGRD1 agonist, activates ADGRD1 by mimicking the Stachel sequence. ADGRD1 negatively regulates osteoclastogenesis via the cAMP-PKA-NFATC1 signaling pathway, and GL64 administration prevents bone loss in an ovariectomy mouse model. Small-molecule agonist identification, cAMP assay, PKA and NFATC1 pathway analysis, osteoclast differentiation assay, ovariectomy mouse model Science advances High 40644539
2025 GPR133 exhibits constitutive self-activation via its Stachel sequence and can activate downstream G13 signaling in addition to Gs. A cryo-EM structure of the GPR133-GAIN-miniGα13 complex was resolved at 3.51 Å, revealing both conserved and distinct features compared to the previously resolved GPR133-CTF-Gs complex. Cryo-EM structure determination (3.51 Å), in vitro reconstitution of GPR133-GAIN-miniGα13 complex, G13 signaling assay Biochemical and biophysical research communications Medium 40570642
2024 GPR133 upregulation in decidual macrophages (caused by promoter hypomethylation) impairs phagocytic function; GPR133 knockdown in THP-1 macrophages significantly improves phagocytic function. 5-Aza-dC demethylation, siRNA/shRNA knockdown, phagocytosis assay in decidual macrophages and THP-1 cells Epigenetics Medium 38564758
2025 ADGRD1 promotes differentiation of adipose progenitor cells (APCs) in vitro and in vivo. In an obese mouse model (high-fat diet), gain-of-function and loss-of-function studies validated that ADGRD1 promotes adipogenesis and improves metabolic homeostasis. Transcription factors MEF2D and TCF12 were identified as regulators of ADGRD1 expression. Single-nucleus sequencing trajectory inference, primary APC differentiation assay, gain- and loss-of-function in HFD mouse model, ChIP-seq and RNA-seq analysis Science China. Life sciences Medium 39821834

Source papers

Stage 0 corpus · 24 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2014 A tethered agonist within the ectodomain activates the adhesion G protein-coupled receptors GPR126 and GPR133. Cell reports 231 25533341
2022 Structural basis of tethered agonism of the adhesion GPCRs ADGRD1 and ADGRF1. Nature 105 35418679
2011 Cell adhesion receptor GPR133 couples to Gs protein. The Journal of biological chemistry 95 22025619
2009 Genetic variation in GPR133 is associated with height: genome wide association study in the self-contained population of Sorbs. Human molecular genetics 61 19729412
2016 GPR133 (ADGRD1), an adhesion G-protein-coupled receptor, is necessary for glioblastoma growth. Oncogenesis 51 27775701
2021 Control of oviductal fluid flow by the G-protein coupled receptor Adgrd1 is essential for murine embryo transit. Nature communications 40 33623007
2021 Functional impact of intramolecular cleavage and dissociation of adhesion G protein-coupled receptor GPR133 (ADGRD1) on canonical signaling. The Journal of biological chemistry 32 34022221
2020 Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes. Neuro-oncology advances 17 32642706
2022 Activation of the adhesion G protein-coupled receptor GPR133 by antibodies targeting its N-terminus. The Journal of biological chemistry 16 35447113
2023 PTK7 is a positive allosteric modulator of GPR133 signaling in glioblastoma. Cell reports 15 37354459
2016 Functional relevance of naturally occurring mutations in adhesion G protein-coupled receptor ADGRD1 (GPR133). BMC genomics 13 27516204
2025 The mechanosensitive adhesion G protein-coupled receptor 133 (GPR133/ADGRD1) enhances bone formation. Signal transduction and targeted therapy 5 40583059
2025 Exogenous activation of the adhesion GPCR ADGRD1/GPR133 protects against bone loss by negatively regulating osteoclastogenesis. Science advances 4 40644539
2024 Modulation of GPR133 (ADGRD1) signaling by its intracellular interaction partner extended synaptotagmin 1. Cell reports 4 38758649
2023 Targeting GPR133 via miR-106a-5p inhibits the proliferation, invasion, migration and epithelial-mesenchymal transition (EMT) of glioma cells. The International journal of neuroscience 4 37036013
2025 Systematical identification of regulatory GPCRs by single-cell trajectory inference reveals the role of ADGRD1 and GPR39 in adipogenesis. Science China. Life sciences 3 39821834
2024 Upregulation of GPR133 expression impaired the phagocytosis of macrophages in recurrent spontaneous miscarriage. Epigenetics 2 38564758
2017 Identification of two novel chicken GPR133 variants and their expression in different tissues. Functional & integrative genomics 2 28612136
2025 Cryo-EM structural elucidation and molecular mechanism of the GPR133-G13 signaling complex. Biochemical and biophysical research communications 1 40570642
2024 Upregulation of mRNA Expression of ADGRD1/GPR133 and ADGRG7/GPR128 in SARS-CoV-2-Infected Lung Adenocarcinoma Calu-3 Cells. Cells 1 38786015
2026 Loss of GPR133 Promotes Enzalutamide Resistance in Prostate Cancer by Upregulating HSD3B1 and Intratumoral Androgen Synthesis. The Prostate 0 41664980
2026 Cryo-EM structures of GPR133 from basal organisms elucidate evolutionary conservation and divergence of its activation. Biochemical and biophysical research communications 0 42214916
2025 Circular RNA circNRIP1 promotes glioma progression by regulating the miR-106a-5p/GPR133 pathway. Scientific reports 0 41225028
2023 Modulation of GPR133 (ADGRD1) Signaling by its Intracellular Interaction Partner Extended Synaptotagmin 1 (ESYT1). bioRxiv : the preprint server for biology 0 36798364

Missed literature

Know a paper Affinage missed for ADGRD1? Flag it for the maintainers and the community.

No submissions yet.